INO Inovio Pharmaceuticals Inc

Price (delayed)

$7.02

Market cap

$1.48B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.65

Enterprise value

$1.45B

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO ...

Highlights
The gross profit has surged by 136% year-on-year
INO's revenue has soared by 136% year-on-year
The equity has soared by 173% YoY but it has contracted by 13% from the previous quarter
INO's quick ratio is down by 31% since the previous quarter and by 11% year-on-year

Key stats

What are the main financial stats of INO
Market
Shares outstanding
210.36M
Market cap
$1.48B
Enterprise value
$1.45B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.89
Price to sales (P/S)
227.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
224.68
Earnings
Revenue
$6.46M
EBIT
-$137.68M
EBITDA
-$133.25M
Free cash flow
-$258.46M
Per share
EPS
-$0.65
Free cash flow per share
-$1.23
Book value per share
$2.43
Revenue per share
$0.03
TBVPS
$2.76
Balance sheet
Total assets
$591.84M
Total liabilities
$83.29M
Debt
$33.8M
Equity
$508.55M
Working capital
$490.68M
Liquidity
Debt to equity
0.07
Current ratio
10.48
Quick ratio
8.84
Net debt/EBITDA
0.19
Margins
EBITDA margin
-2,062.5%
Gross margin
100%
Net margin
-2,193.4%
Operating margin
-3,117.7%
Efficiency
Return on assets
-25.5%
Return on equity
-30.2%
Return on invested capital
-34.4%
Return on capital employed
-25.5%
Return on sales
-2,131%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INO stock price

How has the Inovio Pharmaceuticals stock price performed over time
Intraday
-1.96%
1 week
7.18%
1 month
-7.27%
1 year
-42.51%
YTD
-20.68%
QTD
-1.96%

Financial performance

How have Inovio Pharmaceuticals's revenue and profit performed over time
Revenue
$6.46M
Gross profit
$6.46M
Operating income
-$201.43M
Net income
-$141.71M
Gross margin
100%
Net margin
-2,193.4%
The gross profit has surged by 136% year-on-year
INO's revenue has soared by 136% year-on-year
INO's operating income has shrunk by 79% YoY and by 33% QoQ
Inovio Pharmaceuticals's net margin has surged by 73% YoY and by 25% QoQ

Growth

What is Inovio Pharmaceuticals's growth rate over time

Valuation

What is Inovio Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.89
P/S
227.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
224.68
INO's EPS has surged by 62% year-on-year and by 40% since the previous quarter
The equity has soared by 173% YoY but it has contracted by 13% from the previous quarter
The stock's price to book (P/B) is 72% less than its 5-year quarterly average of 10.2 and 30% less than its last 4 quarters average of 4.1
INO's revenue has soared by 136% year-on-year
The P/S is 46% lower than the last 4 quarters average of 421.5 but 13% higher than the 5-year quarterly average of 202.3

Efficiency

How efficient is Inovio Pharmaceuticals business performance
INO's ROE has soared by 86% YoY and by 38% from the previous quarter
INO's return on sales has surged by 72% year-on-year and by 24% since the previous quarter
INO's return on assets has surged by 69% year-on-year and by 30% since the previous quarter
The company's return on invested capital has surged by 64% YoY and by 35% QoQ

Dividends

What is INO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INO.

Financial health

How did Inovio Pharmaceuticals financials performed over time
The company's total liabilities has shrunk by 68% YoY but it rose by 14% QoQ
The total assets has grown by 34% year-on-year but it has declined by 10% since the previous quarter
Inovio Pharmaceuticals's debt is 93% lower than its equity
The equity has soared by 173% YoY but it has contracted by 13% from the previous quarter
The debt to equity has plunged by 87% YoY but it has grown by 17% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.